Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03546205 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
A Phase 1 study of Kidney Failure, Chronic, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT03546205 is a Phase 1 study of Kidney Failure, Chronic that has completed, run by Janssen Research & Development. The registered enrollment target is 40 participants, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03546205, a Phase 1 study of Kidney Failure, Chronic, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of study is to evaluate the pharmacokinetics of a single, subcutaneous dose of JNJ-64565111 in adult participants with varying degrees of renal function including participants with end stage renal disease, requiring hemodialysis, compared with participants with normal renal function.
Conditions Studied
Interventions
- DRUG JNJ-64565111
Study Locations (2)
Florida
- Orlando Clinical Research Center - Orlando
Tennessee
- AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2018-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03546205
The ClinicalTrials.gov registry entry for NCT03546205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (88% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 1 intervention - of which JNJ-64565111 is the first listed.
NCT03546205 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03546205 about?
NCT03546205 is a clinical study titled "A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function". The purpose of study is to evaluate the pharmacokinetics of a single, subcutaneous dose of JNJ-64565111 in adult participants with varying degrees of renal function including participants with end stage renal disease, requiring hemodialysis, compared with participants with normal renal function.
What is the current status of trial NCT03546205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-06-06. Estimated completion is 2018-12-17.
What conditions does trial NCT03546205 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic.
What interventions are being tested in trial NCT03546205?
The interventions under investigation include: JNJ-64565111 (DRUG).
Who is sponsoring clinical trial NCT03546205?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03546205 being conducted?
This trial has 2 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
COMPLETED · Phase 1
-
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
COMPLETED · Phase 1
-
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.